Same Drug Interactions, Uses, Effectiveness, Safety & More
What is this page for?
First and foremost: how Same interacts with medications. The heart of this page is the interaction list — every drug Same is known to interact with, and how serious each one is.
But these pages have grown well beyond that into a full monograph — what Same is, what people use it for and how strong the evidence is, its safety and side effects, and answers to the questions we’re asked most — written and reviewed by the clinical staff at HelloPharmacist. It’s educational information from our licensed clinical databases, not medical advice, and we don’t sell or endorse products. Our editorial policy
Check Same against your medication
Add one medicationSame Drug Interactions: The Bottom Line
From the HelloPharmacist Editorial Team · Updated July 2026Based on the available evidence, the overall risk of a clinically significant Same drug interaction appears low for most people, though anyone taking mood or Parkinson's medications should pay closer attention. None of the listed interactions are rated major, and nearly all rest on theoretical reasoning or limited case reports rather than well-controlled human studies.
The combination that deserves the most care is Same with serotonergic drugs, a group that includes many antidepressants, because Same itself acts on serotonin and adding it to these medicines could raise the risk of serotonin syndrome, a reaction marked by agitation, rapid heart rate, and high body temperature. This concern comes mainly from one case report, so it is not well established, but the potential outcome makes caution sensible. People taking levodopa for Parkinson's disease should also know that Same might chemically alter levodopa in a way that could make it work less well.
The long list of interacting medications looks daunting, but most entries are there because they belong to the broad serotonergic group. These interactions are largely predicted from how Same works in the body, not from documented harm in people, so the sheer number overstates the real-world risk for most combinations.
Based on HelloPharmacist’s Same interaction data and reviewed under our editorial standards.
Drugs that interact with Same
189 medications have a known interaction with Same, graded by severity. Select any drug for the full evidence-based detail.
Don’t want to scroll the list? Just ask.
Tell us the medications you take and we’ll check each one against Same using our pharmacist-reviewed interaction data.
AI summaries are generated from our Same interaction data for education only — always confirm with your pharmacist. How we use AI
No drugs match “”.
What Severity, Likelihood & Evidence Mean
Severity — How Serious It Can Be
- Major. Clinically significant; generally best avoided, or used only under direct professional supervision.
- Moderate. May need monitoring, a dose adjustment, or separating the times you take each one.
- Minor. Generally not clinically significant, but still worth noting and mentioning to your pharmacist.
- No known interaction. Checked against our sources with nothing documented — not the same as proven safety.
Likelihood — How Well It’s Documented
- Likely. Well-controlled human studies have demonstrated the likely existence of this interaction
- Probable. Interaction has not been documented in well-controlled studies, however, the interaction has been demonstrated in some small human studies or in controlled animal studies in conjunction with multiple case reports.
- Possible. Interaction has been documented in animal or in lab research, or the interaction has been documented in humans but is limited to case reports or conflicting clinical research exists
- Unlikely. Interaction has been demonstrated in animal or in lab research but has been shown not to occur in humans.
Where This Data Comes From
- Interaction records are evidence-graded and sourced from the Natural Medicines database (TRC Healthcare), the same reference used by pharmacists and hospitals.
- Each drug listed above links to the full report for that exact Same combination — clinical detail, likelihood, evidence level, and citations.
- Content is reviewed by licensed HelloPharmacist pharmacists — see our data sources and editorial standards.
The kinds of drugs Same affects
Every type of medication (drug category) Same is known to interact with. Open any category for the detail — or search your exact drug in the checker above.
Levodopa
SAMe might reduce the effectiveness of levodopa.
SAMe methylates levodopa, which might reduce its effectiveness for treating Parkinson disease.
Serotonergic Drugs
Taking SAMe with serotonergic drugs might increase the risk of serotonin syndrome and other serotonergic side effects.
SAMe has serotonergic effects. Theoretically, combining serotonergic drugs with SAMe might increase the risk of serotonergic side effects, including serotonin syndrome and cerebral vasoconstrictive disorders. In one case report, SAMe 100 mg intramuscularly was given daily with clomipramine (Anafranil) 25 mg per day. When the clomipramine dose was increased to 75 mg per day the patient experienced serotonin syndrome about 48-72 hours later, requiring hospitalization.
Same: Uses, Safety & Side Effects
SAM-e is a compound your body makes naturally that is sold as a supplement, most often for depression and osteoarthritis. Some research suggests it may help with these conditions, but the quality of evidence is mixed and more study is needed. Talk with your pharmacist or doctor before trying it, especially if you take other medicines or have bipolar disorder.

- Part used
- Not a plant; a compound made naturally in the body (supplements are made synthetically)
- Common forms
- Enteric-coated tablets, capsules; less commonly injectable (used in some countries under medical supervision)
- Depression
- Osteoarthritis joint pain
- Liver conditions
- Fibromyalgia
Popular and traditional uses — not proof it works. See “Uses & effectiveness” below for the evidence.
Often well tolerated short-term, but it can cause stomach upset and may trigger mania in people with bipolar disorder.
When used intravenously short-term during the third trimester of pregnancy. In two small-scale trials, SAMe 800 mg daily was used intravenously for 14...
Read the full pregnancy detailInsufficient reliable information available; avoid using.
Read the full breastfeeding detailPregnancy & breastfeeding ratings are from Natural Medicines (Therapeutic Research Center). Safety guidance is general; always confirm with your pharmacist or doctor for your situation.
Overview
SAM-e (S-adenosyl-L-methionine) is a compound that your body makes naturally from an amino acid called methionine and a molecule called ATP. It is found in nearly every cell and plays a role in many chemical reactions, including making neurotransmitters (brain messengers) and processing hormones.
Because it is a natural body compound rather than a plant, the SAM-e in supplements is made in a laboratory. It is sold as a dietary supplement in the United States, and in some other countries it is available as a prescription medicine (called ademetionine).
People most often take SAM-e supplements to help with symptoms of depression and the joint pain of osteoarthritis. It has also been studied for liver problems and fibromyalgia.
How it works
SAM-e acts as a methyl donor, meaning it passes along small chemical groups (methyl groups) needed for many reactions in the body. This process, called methylation, helps make and break down neurotransmitters such as serotonin, dopamine, and norepinephrine, which may explain its possible role in mood.
SAM-e is also involved in building cartilage components, which is one proposed reason it might help with osteoarthritis. In the liver, it helps with detoxification reactions and the handling of bile.
Many of these mechanisms are based on laboratory and animal research, and it is not fully understood exactly how SAM-e taken by mouth produces its effects in people.
Does Same work?
How to read these evidence grades
Natural Medicines’ 7-point scale. We show each rating’s label word-for-word.
Likely Effective Osteoarthritis
Multiple studies show that oral SAMe can decrease symptoms and improve function in patients with osteoarthritis similarly to non-steroidal anti-inflammatory drugs (NSAIDs), although with a slower onset of action.
Possibly Effective Cholestasis
Clinical research suggests that oral or intravenous SAMe is similarly effective to ursodeoxycholic acid (ursodiol) for treatment of cholestasis.
Possibly Effective Depression
Most short-term clinical studies suggest that SAMe modestly improves symptoms in adults with depression. However, it does not seem to improve the effects of antidepressants when used as adjunctive therapy. Additionally, the benefits of SAMe when used for more than 3 months remain unclear.
Also studied for 19 conditions — evidence insufficient to rate
Insufficient Reliable Evidence To Rate Aging
Although there is interest in using oral SAMe for aging, there is insufficient reliable information about the clinical effects of SAMe for this purpose.
Insufficient Reliable Evidence To Rate Alcohol-related liver disease
It is unclear if oral or intravenous SAMe is beneficial in patients with alcohol-related liver disease.
Insufficient Reliable Evidence To Rate Alzheimer disease
Although there is interest in using oral SAMe for Alzheimer disease, there is insufficient reliable information about the clinical effects of SAMe for this condition.
Insufficient Reliable Evidence To Rate Antidepressant-induced sexual dysfunction
Oral SAMe might improve sexual dysfunction in males taking antidepressants.
Insufficient Reliable Evidence To Rate Attention deficit-hyperactivity disorder (ADHD)
It is unclear whether oral SAMe is beneficial in patients with ADHD.
Insufficient Reliable Evidence To Rate Back pain
Although there is interest in using oral SAMe for back pain, there is insufficient reliable information about the clinical effects of SAMe for this condition.
Insufficient Reliable Evidence To Rate Cancer-related fatigue
It is unclear if oral SAMe is beneficial in patients with cancer-related fatigue.
Insufficient Reliable Evidence To Rate Chronic fatigue syndrome (CFS)
Although there is interest in using oral SAMe for CFS, there is insufficient reliable information about the clinical effects of SAMe for this condition.
Insufficient Reliable Evidence To Rate Epilepsy
Although there has been interest in using oral SAMe for epilepsy, there is insufficient reliable information about the clinical effects of SAMe for this condition.
Insufficient Reliable Evidence To Rate Fibromyalgia
Limited evidence shows that oral or intramuscular SAMe might modestly improve some symptoms of fibromyalgia.
Insufficient Reliable Evidence To Rate Gilbert syndrome
It is unclear if oral SAMe is beneficial in patients with this condition.
Insufficient Reliable Evidence To Rate Hepatitis C
It is unclear if oral SAMe is beneficial in patients with hepatitis C.
Insufficient Reliable Evidence To Rate Lead toxicity
Although there has been interest in using oral or intravenous SAMe for lead toxicity, there is insufficient reliable information about the clinical effects of SAMe for this purpose.
Insufficient Reliable Evidence To Rate Menopausal symptoms
It is unclear if oral SAMe is beneficial for menopausal hot flashes.
Insufficient Reliable Evidence To Rate Migraine headache
Although there is interest in using oral SAMe for migraine, there is insufficient reliable information about the clinical effects of SAMe for this purpose.
Insufficient Reliable Evidence To Rate Multiple sclerosis (MS)
Although there is interest in using oral SAMe for MS, there is insufficient reliable information about the clinical effects of SAMe for this condition.
Insufficient Reliable Evidence To Rate Premenstrual syndrome (PMS)
Although there is interest in using oral SAMe for PMS, there is insufficient reliable information about the clinical effects of SAMe for this condition.
Insufficient Reliable Evidence To Rate Schizophrenia
It is unclear if oral SAMe is beneficial in patients with schizophrenia.
Insufficient Reliable Evidence To Rate Tobacco and nicotine dependence
A small clinical study in cigarette smokers suggests that oral SAMe does not improve rates of smoking abstinence.
Source & disclaimer. Effectiveness ratings and evidence summaries are provided by Natural Medicines (Therapeutic Research Center) and shown as licensed. Where Natural Medicines hasn’t rated a use, HelloPharmacist’s pharmacists may add their own reviewed rating and evidence (each such entry is labeled). This is educational information, not medical advice — talk with your pharmacist or doctor before starting, stopping, or changing a supplement.
Safety & precautions
SAM-e is generally well tolerated by many people when used short-term, but there are important cautions. People with bipolar disorder should avoid SAM-e unless directed by a doctor, because it may trigger mania or a switch into a manic episode.
People with Parkinson's disease, anxiety disorders, or those who are scheduled for surgery should talk with their doctor first. Because SAM-e affects brain chemicals, it should be used carefully in anyone taking other products that affect mood or serotonin.
For pregnancy, the safety of supplemental SAM-e is not well established, so it should only be used under medical supervision. For breastfeeding, there is not enough reliable information, so it is best to avoid it or use it only with your doctor's guidance. Always check with a pharmacist or doctor before starting SAM-e.
Side effects
The most common side effects are stomach-related, such as nausea, gas, diarrhea, or upset stomach. Some people also report dry mouth, headache, dizziness, restlessness, or trouble sleeping, especially if taken later in the day.
At higher doses or in sensitive people, SAM-e may cause anxiety or, rarely, may worsen mood or trigger mania in people prone to bipolar disorder. If you notice unusual agitation, racing thoughts, confusion, or a fast heartbeat, stop taking it and seek medical advice.
Same: Reported Adverse Effects
Documented safety reports on Same from the evidence-graded Natural Medicines (TRC Healthcare) database, shown word-for-word from the licensed record.
Orally, SAMe is generally well tolerated when used in typical doses. Side effects are more common with higher doses.
Most Common Adverse Effects:
Orally: Anorexia, constipation, diarrhea, dizziness, dry mouth, flatulence, headache, insomnia, nausea, nervousness, sweating, vomiting.
Alopecia Dermatologic
Orally, SAMe may cause rash and itching, transient hair loss, sweating, and night sweats.
Intravenously, SAMe may cause rash and sweating.
- Rosenbaum JF, Fava M, Falk WE, et al. The antidepressant potential of oral S-adenosyl-l-methionine. Acta Psychiatr Scand 1990;81:432-6.
- Domljan Z, Vrhovac B, Durrigl T, Pucar I. A double-blind trial of ademetionine vs naproxen in activated gonarthrosis. Int J Clin Pharmacol Ther Toxicol 1989;27:329-33.
- Konig B. A long-term (two years) clinical trial with S-adenosylmethionine for the treatment of osteoarthritis. Am J Med 1987;83:89-94.
- Kim J, Lee EY, Koh EM, et al. Comparative clinical trial of S-adenosylmethionine versus nabumetone for the treatment of knee osteoarthritis: an 8-week, multicenter, randomized, double-blind, double-dummy, Phase IV study in Korean patients. Clin Ther 2009;
- Medici V., Virata M. C., Peerson J. M., Stabler S. P., French S. W., Gregory J. F. III, Albanese A., Bowlus C. L., Devaraj S., Panacek E. A., Richards J. R., Halsted C. H. S-adenosyl-L-methionine treatment for alcoholic liver disease: a double-blinded, ra
- Capretto C, Cremona C, and Canaparo L. A double-blind controlled study of S-adenosylmethionine (SAMe) v. ibuprofen in gonarthrosis, coxarthrosis and spondylarthrosis. Clin Trials J 1985;22(1):15-24.
- Manzillo G, Piccinino F, Surrenti C, et al. Multicentre double-blind placebo-controlled study of intravenous and oral S-adenosyl-L-methionine (SAMe) in cholestatic patients with liver disease. Drug Invest 1992;4 (Suppl 4):90-100.
- Bacci, Ballerini F., Lopez, Anguera A., Alcaraz, P., and Hernandez, Reyes N. [SAMe in the management of postconcussional syndrome]. Medicina Clinica (Barc.) 1983;80(4):161-164.
- Ancarani E, Biondi B, Bolletta A, et al. Major depression complicating hemodialysis in patients with chronic renal failure: a multicenter, double-blind, controlled clinical trial of S-adenosyl-L-methionine versus placebo. Curr Ther Res 1993;54(6):680-6.
Anorexia Gastrointestinal
When taken orally or given intravenously, SAMe may cause increased salivation, bloating, flatulence, nausea, vomiting, diarrhea, stomach ache, heartburn, constipation, hunger, thirst, anorexia, blood in the stool, and dry mouth.
Anxiety Psychiatric
Orally, anxiety and tiredness have been reported in patients with depression. Rare adverse effects associated with SAMe include hypermania. Hypomania has occurred with a combination of intramuscular and oral SAMe. Cases of mania with suicidal ideation have also been reported in otherwise healthy patients. A crawling sensation on the skin has been reported in a clinical trial. In a case report, a patient with depression self-medicated with oral SAMe and attempted suicide four days later.
When used as an injection, rarely SAMe has caused both hypermania and hypomania in people with bipolar disorder or depression. Two suicide attempts occurred in a clinical trial of intramuscular SAMe in patients with major depression.
- Friedel HA, Goa KL, Benfield P. S-adenosyl-L-methionine. A review of its pharmacological properties and therapeutic potential in liver dysfunction and affective disorders in relation to its physiological role in cell metabolism. Drugs 1989;38:389-416.
- Arnold O, Saletu B, Anderer P, et al. Double-blind, placebo-controlled pharmacodynamic studies with a nutraceutical and a pharmaceutical dose of ademetionine (SAMe) in elderly subjects, utilizing EEG mapping and psychometry. Eur Neuropsychopharmacol 2005;
- Rosenbaum JF, Fava M, Falk WE, et al. The antidepressant potential of oral S-adenosyl-l-methionine. Acta Psychiatr Scand 1990;81:432-6.
- Carrieri PB, Indaco A, Gentile S, et al. S-adenosylmethionine treatment of depressioin in patients with Parkinson's disease: a double-blind, crossover study versus placebo. Curr Ther Res 1990;48(1):154-60.
- Kagan BL, Sultzer DL, Rosenlicht N, Gerner RH. Oral S-adenosylmethionine in depression: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry 1990;147:591-5.
- Goren JL, Stoll AL, Damico KE, et al. Bioavailability and lack of toxicity of S-adenosyl-L-methionine (SAMe) in humans. Pharmacotherapy 2004;24:1501-7.
- Chitiva, H., Audivert, F., and Alvarez, C. Suicide attempt by self-burning associated with ingestion of S-adenosylmethionine: a review of the literature and case report. J.Nerv.Ment.Dis. 2012;200(1):99-101.
- Lipinski JF, Cohen BM, Frankenburg F, et al. Open trial of S-adenosylmethionine for treatment of depression. Am J Psychiatry 1984;141:448-50.
- Nelson JC. S-adenosyl methionine (SAMe) augmentation in major depressive disorder. (Editorial). Am J Psychiatry 2010;167:889-91.
- Carney, M. W., Edeh, J., Bottiglieri, T., Reynolds, E. M., and Toone, B. K. Affective illness and S-adenosyl methionine: a preliminary report. Clin Neuropharmacol. 1986;9(4):379-385.
- Pancheri P, Scapicchio P, Delle Chiaie R. A double-blind, randomized parallel-group, efficacy and safety study of intramuscular S-adenosyl-L-methionine 1,4-butanedisulphonate (SAMe) versus imipramine in patients with major depressive disorder. Int J Neuro
Anxiety Neurologic/CNS
Orally, SAMe may cause vertigo, headache, insomnia, fatigue, tremors, agitation, dizziness, vivid dreams, and anxiety.
Intramuscularly, SAMe may cause insomnia , anxiety, hostility, dizziness and drowsiness, and headache, although these events are rare.
Intravenously, side effects rarely associated with SAMe include insomnia, anxiety, and psychomotor agitation.
- Bradley JD, Flusser D, Katz BP, et al. A randomized, double blind, placebo controlled trial of intravenous loading with S-adenosylmethionine (SAM) followed by oral SAM therapy in patients with knee osteoarthritis. J Rheumatol 1994;21:905-11.
- Carrieri PB, Indaco A, Gentile S, et al. S-adenosylmethionine treatment of depressioin in patients with Parkinson's disease: a double-blind, crossover study versus placebo. Curr Ther Res 1990;48(1):154-60.
- Muscettola G, Galzenati M, Balbi A. SAMe versus placebo: a double blind comparison in major depressive disorders. Advances in Biochemical Psychopharmacology 1982;32:151-6.
- Manzillo G, Piccinino F, Surrenti C, et al. Multicentre double-blind placebo-controlled study of intravenous and oral S-adenosyl-L-methionine (SAMe) in cholestatic patients with liver disease. Drug Invest 1992;4 (Suppl 4):90-100.
- Carney, M. W., Edeh, J., Bottiglieri, T., Reynolds, E. M., and Toone, B. K. Affective illness and S-adenosyl methionine: a preliminary report. Clin Neuropharmacol. 1986;9(4):379-385.
- Miccoli, L., Porro, V., and Bertolino, A. Comparison between the antidepressant activity and of S- adenosylmethionine (SAMe) and that of some tricyclic drugs. Acta Neurol (Napoli) 1978;33 (3):243-255.
- Ancarani E, Biondi B, Bolletta A, et al. Major depression complicating hemodialysis in patients with chronic renal failure: a multicenter, double-blind, controlled clinical trial of S-adenosyl-L-methionine versus placebo. Curr Ther Res 1993;54(6):680-6.
Cirrhosis Cardiovascular
There has been some concern that SAMe might increase homocysteine levels. SAMe is metabolized to s-adenosylhomocysteine, which can be metabolized to homocysteine. Elevated levels of homocysteine have been linked to cardiovascular and kidney disease. However, in a study lasting 4 weeks, administration of SAMe orally in doses titrated up to 1600 mg daily was not associated with a significant increase in homocysteine levels. In another study, there also was no difference in cardiovascular mortality in people with cirrhosis taking SAMe 1200 mg daily for 2 years.
Intravenously, SAMe infusions may cause phlebitis. Also, a case of tachycardia has been reported in a patient treated with intravenous SAMe.
- Bottiglieri T, Hyland K, Reynolds EH. The clinical potential of ademetionine (S-adenosylmethionine) in neurological disorders. Drugs 1994;48:137-52.
- Perna AF, Castaldo P, Ingrosso D, et al. Homocysteine, a new cardiovascular risk factor, is also a powerful uremic toxin. J Nephrol 1999;12:230-40.
- Goren JL, Stoll AL, Damico KE, et al. Bioavailability and lack of toxicity of S-adenosyl-L-methionine (SAMe) in humans. Pharmacotherapy 2004;24:1501-7.
- Mato JM, Camara J, Fernandez de Paz J, et al. S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. J Hepatol 1999;30:1081-9.
- Manzillo G, Piccinino F, Surrenti C, et al. Multicentre double-blind placebo-controlled study of intravenous and oral S-adenosyl-L-methionine (SAMe) in cholestatic patients with liver disease. Drug Invest 1992;4 (Suppl 4):90-100.
- Miccoli, L., Porro, V., and Bertolino, A. Comparison between the antidepressant activity and of S- adenosylmethionine (SAMe) and that of some tricyclic drugs. Acta Neurol (Napoli) 1978;33 (3):243-255.
Adverse-effects data: Natural Medicines, Therapeutic Research Center
Dosing
There is no single official standardized dose of SAM-e, and the amount studied has varied depending on the condition and the salt form used. Different products may contain different forms (such as butanedisulfonate or tosylate disulfate), which can affect how well the body absorbs them.
Because of this, it is best to follow the directions on the product label and check with your pharmacist or doctor about an appropriate dose for you. SAM-e is often sold as enteric-coated tablets to help it survive stomach acid, and some people take it before meals.
Do not assume more is better. Starting low and using the lowest helpful dose may reduce the chance of side effects.
Same & Pregnancy
Same & Breastfeeding
© 2026 Therapeutic Research Center
Pregnancy & lactation ratings: Natural Medicines, Therapeutic Research Center
References & further reading
The 31 references that drive our Same monograph and interaction data, from the evidence-graded Natural Medicines (TRC Healthcare) database. Citations with a link open the study on PubMed or the publisher’s site.
- Perna AF, Castaldo P, Ingrosso D, et al. Homocysteine, a new cardiovascular risk factor, is also a powerful uremic toxin. J Nephrol 1999;12:230-40.
- Mato JM, Camara J, Fernandez de Paz J, et al. S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. J Hepatol 1999;30:1081-9. PubMed
- Iruela LM, Minguez L, Merino J, Monedero G. Toxic interaction of S-adenosylmethionine and clomipramine. Am J Psychiatry 1993;150:522. PubMed
- Bradley JD, Flusser D, Katz BP, et al. A randomized, double blind, placebo controlled trial of intravenous loading with S-adenosylmethionine (SAM) followed by oral SAM therapy in patients with knee osteoarthritis. J Rheumatol 1994;21:905-11.
- Berlanga C, Ortega-Soto HA, Ontiveros M, Senties H. Efficacy of S-adenosyl-L-methionine in speeding the onset of action of imipramine. Psychiatry Res 1992;44:257-62. PubMed
- Kagan BL, Sultzer DL, Rosenlicht N, Gerner RH. Oral S-adenosylmethionine in depression: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry 1990;147:591-5. PubMed
- Rosenbaum JF, Fava M, Falk WE, et al. The antidepressant potential of oral S-adenosyl-l-methionine. Acta Psychiatr Scand 1990;81:432-6. PubMed
- Domljan Z, Vrhovac B, Durrigl T, Pucar I. A double-blind trial of ademetionine vs naproxen in activated gonarthrosis. Int J Clin Pharmacol Ther Toxicol 1989;27:329-33.
- Konig B. A long-term (two years) clinical trial with S-adenosylmethionine for the treatment of osteoarthritis. Am J Med 1987;83:89-94. PubMed
- Lipinski JF, Cohen BM, Frankenburg F, et al. Open trial of S-adenosylmethionine for treatment of depression. Am J Psychiatry 1984;141:448-50.
- Almasio P, Bortolini M, Pagliaro L, Coltorti M. Role of S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis. Drugs 1990;40:111-23. PubMed
- Friedel HA, Goa KL, Benfield P. S-adenosyl-L-methionine. A review of its pharmacological properties and therapeutic potential in liver dysfunction and affective disorders in relation to its physiological role in cell metabolism. Drugs 1989;38:389-416. PubMed
- Bottiglieri T, Hyland K, Reynolds EH. The clinical potential of ademetionine (S-adenosylmethionine) in neurological disorders. Drugs 1994;48:137-52. PubMed
- Frezza M, Centini G, Cammareri G, et al. S-adenosylmethionine for the treatment of intrahepatic cholestasis of pregnancy. Results of a controlled clinical trial. Hepatogastroenterology 1990;37:122-5.
- Singhal AB, Caviness VS, Begleiter AF, et al. Cerebral vasoconstriction and stroke after use of serotonergic drugs. Neurology 2002;58:130-3. PubMed
- Charlton CG, Crowell B Jr. Parkinson's disease-like effects of S-adenosyl-L-methionine: effects of L-dopa. Pharmacol Biochem Behav 1992;43:423-31..
- Goren JL, Stoll AL, Damico KE, et al. Bioavailability and lack of toxicity of S-adenosyl-L-methionine (SAMe) in humans. Pharmacotherapy 2004;24:1501-7. PubMed
- Arnold O, Saletu B, Anderer P, et al. Double-blind, placebo-controlled pharmacodynamic studies with a nutraceutical and a pharmaceutical dose of ademetionine (SAMe) in elderly subjects, utilizing EEG mapping and psychometry. Eur Neuropsychopharmacol 2005; PubMed
- Nelson JC. S-adenosyl methionine (SAMe) augmentation in major depressive disorder. (Editorial). Am J Psychiatry 2010;167:889-91.
- Kim J, Lee EY, Koh EM, et al. Comparative clinical trial of S-adenosylmethionine versus nabumetone for the treatment of knee osteoarthritis: an 8-week, multicenter, randomized, double-blind, double-dummy, Phase IV study in Korean patients. Clin Ther 2009; PubMed
- Manzillo G, Piccinino F, Surrenti C, et al. Multicentre double-blind placebo-controlled study of intravenous and oral S-adenosyl-L-methionine (SAMe) in cholestatic patients with liver disease. Drug Invest 1992;4 (Suppl 4):90-100. DOI
- Carrieri PB, Indaco A, Gentile S, et al. S-adenosylmethionine treatment of depressioin in patients with Parkinson's disease: a double-blind, crossover study versus placebo. Curr Ther Res 1990;48(1):154-60.
- Pancheri P, Scapicchio P, Delle Chiaie R. A double-blind, randomized parallel-group, efficacy and safety study of intramuscular S-adenosyl-L-methionine 1,4-butanedisulphonate (SAMe) versus imipramine in patients with major depressive disorder. Int J Neuro PubMed
- Medici V., Virata M. C., Peerson J. M., Stabler S. P., French S. W., Gregory J. F. III, Albanese A., Bowlus C. L., Devaraj S., Panacek E. A., Richards J. R., Halsted C. H. S-adenosyl-L-methionine treatment for alcoholic liver disease: a double-blinded, ra
- Chitiva, H., Audivert, F., and Alvarez, C. Suicide attempt by self-burning associated with ingestion of S-adenosylmethionine: a review of the literature and case report. J.Nerv.Ment.Dis. 2012;200(1):99-101. PubMed
- Carney, M. W., Edeh, J., Bottiglieri, T., Reynolds, E. M., and Toone, B. K. Affective illness and S-adenosyl methionine: a preliminary report. Clin Neuropharmacol. 1986;9(4):379-385. PubMed
- Miccoli, L., Porro, V., and Bertolino, A. Comparison between the antidepressant activity and of S- adenosylmethionine (SAMe) and that of some tricyclic drugs. Acta Neurol (Napoli) 1978;33 (3):243-255.
- Bacci, Ballerini F., Lopez, Anguera A., Alcaraz, P., and Hernandez, Reyes N. [SAMe in the management of postconcussional syndrome]. Medicina Clinica (Barc.) 1983;80(4):161-164.
- Muscettola G, Galzenati M, Balbi A. SAMe versus placebo: a double blind comparison in major depressive disorders. Advances in Biochemical Psychopharmacology 1982;32:151-6.
- Capretto C, Cremona C, and Canaparo L. A double-blind controlled study of S-adenosylmethionine (SAMe) v. ibuprofen in gonarthrosis, coxarthrosis and spondylarthrosis. Clin Trials J 1985;22(1):15-24.
- Ancarani E, Biondi B, Bolletta A, et al. Major depression complicating hemodialysis in patients with chronic renal failure: a multicenter, double-blind, controlled clinical trial of S-adenosyl-L-methionine versus placebo. Curr Ther Res 1993;54(6):680-6. DOI
This information is for education only and is not a substitute for professional medical advice. Always check with your pharmacist or doctor before starting, stopping, or combining supplements and medications.
Parts of this content are provided by the Therapeutic Research Center, LLC.
DISCLAIMER: Currently this does not check for drug-drug interactions. This is not an all-inclusive comprehensive list of potential interactions and is for informational purposes only. Not all interactions are known or well-reported in the scientific literature, and new interactions are continually being reported. Input is needed from a qualified healthcare provider including a pharmacist before starting any therapy. Application of clinical judgment is necessary.
© 2021 Therapeutic Research Center, LLC
Brands that make products with Same
110 brands in our database make a supplement containing Same.
Supplement products with Same
398 products in our database contain Same. Open any to see its full ingredient list and every drug interaction we check.
Same: Common Questions
What is Same used for, and does it work?
Does Same interact with prescription medications?
How are Same interactions rated?
Is it safe to take Same with my medications?
Where does this Same interaction information come from?
What is SAM-e most commonly used for?
Is SAM-e safe to take?
Can I take SAM-e while pregnant or breastfeeding?
How long does SAM-e take to work?
Written and reviewed by the HelloPharmacist editorial staff. Our editorial policy
Products that contain Same
A rotating sample of real supplements in our database that list Same — open any to see its full ingredients and every drug interaction we check.
- Histamine Block Plus by Seeking Health
- SAMe with Vitamins B-6, B-12 and 5-MTHF by Designs for Health
- SAM-e 200 mg by DC
- SAMe 200 mg by Metabolic Maintenance
- SAMe 200 mg by Natural Factors
- SAM-e 200 mg by Rite Aid
- Organ Detox by Garden of Life
- SAM-e 200 mg by SuperSmart
- SAM-e by XYMOGEN
- Take Control by Vitinity
Have a question about Same?
Our pharmacists answer your medication & supplement questions — free.